Disease severity and costs among patients starting a treatment with COX-2 specific inhibitors versus NSAIDs patients in Italy: Quantitative assessment in 442 patients with arthritis

被引：0
|
作者：
Lucioni, C
Chinellato, A
Mazzi, S
Roggeri, D
Chiroli, S
机构：
[1] Adis Int Ltd, Milan, Italy
[2] Serv Farmaceut Terr, Treviso, Italy
[3] Pharmacia Italia SpA, Milan, Italy
来源：
VALUE IN HEALTH | 2002年 / 5卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)61270-3
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：476 / 477
页数：2
相关论文
共 50 条
  • [31] Are We Aware of the Cardiovascular Toxicity of NSAIDS and COX-2 Selective Inhibitors in Patients with Haemophilia? - A Literature Review
    Boban, A.
    Lambert, C.
    Hermans, C.
    HAEMOPHILIA, 2016, 22 : 93 - 94
  • [32] Increased risk of MI with COX-2 inhibitors among patients with history of MI
    不详
    FORMULARY, 2007, 42 (05) : 285 - 285
  • [33] Upper gastrointestinal (UGI) tolerability of valdecoxib, A Cox-2 specific inhibitor, compared with nonspecific (NS) NSAIDs among patients with osteoarthritis (OA) and rheumatoid arthritis (RA)
    Goldstein, JL
    Eisen, GM
    Hanna, DB
    Burke, T
    GASTROENTEROLOGY, 2003, 124 (04) : A511 - A512
  • [34] Safety and efficacy of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis.
    Geis, GS
    Hubbard, R
    Callison, D
    Yu, S
    Zhao, W
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S364 - S364
  • [35] Efficacy and safety of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis.
    Geis, GS
    Stead, H
    Morant, S
    Naudin, R
    Hubbard, R
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S316 - S316
  • [36] Gastrointestinal Toxicity Among Patients Taking Selective Cox-2 Inhibitors or Conventional NSAIDs Alone or Combined with Proton Pump Inhibitors: A Case Control Study
    Bakhriansyah, Mohammad
    Souverein, Patrick C.
    De Boer, Anthonius
    Klungel, Olaf H.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 446 - 446
  • [37] Evaluation of COX-2 Selective Inhibitor for the Protection of Intestinal Mucosal Damage in Comparison to NSAIDs in Patients With Rheumatoid Arthritis
    Inoue, Takahiro
    Iijima, Hideki
    Mukai, Akira
    Hayashi, Yoshito
    Akasaka, Tomofumi
    Kondo, Jumpei
    Nakajima, Sachiko
    Shinzaki, Shinichiro
    Nishida, Tsutomu
    Tsujii, Masahiko
    GASTROENTEROLOGY, 2011, 140 (05) : S388 - S389
  • [38] Korean cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis.
    Yun, HR
    On, KT
    Kim, TH
    Jung, SS
    Yoo, DH
    Kim, SY
    Bae, SC
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S311 - S311
  • [39] Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors
    Scheiman, JM
    Yeomans, ND
    Talley, NJ
    Vakil, N
    Chan, FKL
    Tulassay, Z
    Ralnoldi, JL
    Szczepanski, L
    Ung, JA
    Kleczkowski, D
    Ahlbom, H
    Næsdal, J
    Hawkey, C
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (04): : 701 - 710
  • [40] ACUTE CARDIOVASCULAR ADVERSE REACTION OF COX-2 INHIBITORS AMONG OSTEROARTHRITIS PATIENTS IN TAIWAN
    Chang, C.
    Wang, Y.
    Huang, Y.
    Fann, C. S.
    Chang, C. J.
    VALUE IN HEALTH, 2016, 19 (07) : A915 - A915
12345